Microscopic evaluation of renal changes in experimental canine visceral leishmaniosis after chemo- and immunotherapy.
Visceral Leishmania (VL) with diverse clinical manifestation is prevalent and remains a major public health problem in Iran. This study was performed in Ahwaz, Khozestan province southwest to increase immune system and to reduce of the renal lesions. Treatment of dogs with visceral leishmaniosis is basically the same as the treatment of human. However, cure is not usually achieved, leaving the sacrifice of animal as the only feasible choice. The goal of this work was to test the therapeutic efficacy of N-methyl glutamic antimoate (glucnime), Mycobacterium vaccae adjuvant (SRL 172), alone and in association with L. major promastigote and the latter compound in association to glucantime, in dog with visceral leishmaniasis. In this trial 18, mixed bred dogs with different ages, receiving amastigte promastigote of L. infantum intravenously were used. They were monitored for 6 months. Serologic assays (Elisa, Dot and IFAT) were performed on blood samples of each animal. The animals were divided into six groups, each having 3 dogs: Group 1: receiving 100 mg kg(-1) day(-1) Glucantime for 30 days, IM. Group 2: Receiving 3 mg dog(-1) (0.1 mL) of Mycobacterium vaccae adjuvant suspension intradermaly. Group 3: receiving L. major promastigote plus M. vaccae adjuvant each of them 0.1 mL intradermaly by one month intervals for 3 months. Group 4: receiving Glucantime in association L. major promastigote plus M. vaccae adjuvant with previous doses. Group 5: Receiving no treatment. Group 6: was control group with no infection and treatment. In microscopic evaluation following lesions have been shown in kidney: Chronic, interstitial nephritis, sever glomerulosclerosis, membranoproliferative glomerulonephritis and also non suppurative nephritis were the lesions in 5 groups. The prescription of Mycobacterium vaccae adjurant was able to reduce the number of parasites in the macrophages of liver and spleen in this round of treatment.
Sayari
M
M
Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Avizeh
R
R
Barati
F
F
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000977:Antiparasitic Agents / Q000494:pharmacology; D004283:Dog Diseases / Q000503:physiopathology* / Q000628:therapy; D004285:Dogs; D005921:Glomerulonephritis / Q000473:pathology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007668:Kidney / Q000469:parasitology* / Q000473:pathology*; D007898:Leishmaniasis, Visceral / Q000503:physiopathology* / Q000628:therapy / Q000662:veterinary*; D008099:Liver / Q000469:parasitology; D009393:Nephritis / Q000473:pathology; D013154:Spleen / Q000469:parasitology; D016896:Treatment Outcome
D000913:Antibodies, Protozoan; D000977:Antiparasitic Agents